Condition (MeSH)
Congenital Cranial Dysinnervation Disorders
ClinicalTrials.gov lists 8 trials for Congenital Cranial Dysinnervation Disorders or a narrower condition beneath it.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
1 of the 8 trials are tagged with Congenital Cranial Dysinnervation Disorders itself; the rest are tagged with a narrower condition beneath it.
When did Congenital Cranial Dysinnervation Disorders trials start? (7)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 3
- Phase 4
- Not applicable
- Observational
Top of scale: 2
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2023 | 1 |
| 2020 | 1 |
| 2008 | 1 |
| 2005 | 1 |
| 2004 | 2 |
| 2002 | 1 |
No forecast is made for this condition: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 1 trial still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Congenital Cranial Dysinnervation Disorders trials in? (5)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 3 | 1 |
| Phase 4 | 1 |
| Not applicable | 1 |
| Observational | 4 |
How many Congenital Cranial Dysinnervation Disorders trials are recruiting? (3)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Completed | 5 |
| Unknown status | 1 |
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Congenital Cranial Dysinnervation Disorders trials? (3)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| Gaziosmanpasa Research and Education Hospital | 1 |
| National Human Genome Research Institute (NHGRI) | 1 |
| Rhythm Pharmaceuticals, Inc. | 1 |
Which publications cover Congenital Cranial Dysinnervation Disorders? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Novel variants in TUBA1A cause congenital fibrosis of the extraocular muscles with or without malformations of cortical brain development. | European journal of human genetics : EJHG | 2021 | No |
| Congenital monocular elevation deficiency associated with a novel <i>TUBB3</i> gene variant. | The British journal of ophthalmology | 2020 | No |
| Altered White Matter Organization in the TUBB3 E410K Syndrome. | Cerebral cortex (New York, N.Y. : 1991) | 2019 | No |
| Outcomes of strabismus surgery in genetically confirmed congenital fibrosis of the extraocular muscles. | Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus | 2019 | No |
| Expanding the phenotypic spectrum and variability of endocrine abnormalities associated with TUBB3 E410K syndrome. | The Journal of clinical endocrinology and metabolism | 2015 | No |
Showing 5 of 7 publications.
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: serious adverse events in this condition's trials, prevalence, and rare-disease identity.
Not computed for conditions with fewer than 10 trials: drugs tested.